Utomilumab
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Utomilumab
- DrugBank Accession Number
- DB15113
- Background
Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- PF-05082566
- Utomilumab
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Utomilumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Utomilumab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Utomilumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Utomilumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Utomilumab. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6YY8O697VF
- CAS number
- 1417318-27-4
References
- General References
- Not Available
- External Links
- Wikipedia
- CD137
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Advanced Malignant Neoplasm / Non-Small Cell Lung Cancer (NSCLC) / Ovarian Cancer / Solid Tumors / Urothelial Cancer 1 3 Terminated Treatment Diffuse Large B-Cell Lymphoma (DLBCL) 1 2 Active Not Recruiting Treatment Breast Cancer 1 2 Recruiting Treatment Breast Cancer Stage IIIc / Breast Cancer, Stage III / Breast Cancer, Stage IIIB / Carcinoma Breast Stage IV / Invasive Breast Carcinoma / Recurrent Breast Carcinoma / Stage IIIA Breast Cancer / Triple Negative Breast Carcinoma / Unresectable Breast Carcinoma 1 2 Terminated Treatment Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Oropharyngeal Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 20, 2019 14:50 / Updated at February 21, 2021 18:55